![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » UK MHRA PROPOSES TO COMBINE TWO REVIEW PANELS
UK MHRA PROPOSES TO COMBINE TWO REVIEW PANELS
September 12, 2006
The UK Medicines and Healthcare Products Regulatory Agency (MHRA) has posted a letter on its website proposing a merger of two advisory panels, the Independent Review Panel for Borderline Products and the Independent Review Panel for Advertising. The combined panel would be called the Independent Review Panel for Medicines Advertising and Borderline Products.
The role of the borderline products panel is to advise the MHRA on whether or not it considers a product a medicinal product. The advertising panel advises health ministers on if an advertisement is in breach of advertising regulations. Both panels constitute a legally qualified chairperson and two to four other members who represent consumer interests.
The membership
of both panels is due to expire in March 2007, so the MHRA has taken this opportunity
to review advisory panel structure. The importance of the safeguards provided
by the two panels is clear, and the MHRA does not propose any change to their
functions. However, the terms of reference, criteria for membership and role of
members, the two panels are very similar. A merger of the panels will promote
more efficient use of resources, reducing duplication of membership and allowing
external advisers to be used more regularly and flexibly as the need arises, according
to the MHRA.
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct